141 related articles for article (PubMed ID: 31218911)
1. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Cambron M; Mostert J; D'Hooghe M; Nagels G; Willekens B; Debruyne J; Algoed L; Verhagen W; Hupperts R; Heersema D; De Keyser J;
Mult Scler; 2019 Nov; 25(13):1728-1735. PubMed ID: 31218911
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
Trials; 2014 Jan; 15():37. PubMed ID: 24460863
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
4. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study.
Mostert JP; Admiraal-Behloul F; Hoogduin JM; Luyendijk J; Heersema DJ; van Buchem MA; De Keyser J
J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1027-31. PubMed ID: 18450787
[TBL] [Abstract][Full Text] [Related]
6. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
[TBL] [Abstract][Full Text] [Related]
7. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
8. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Foley P; Parker RA; de Angelis F; Connick P; Chandran S; Young C; Weir CJ; Chataway J;
Mult Scler Relat Disord; 2022 Jul; 63():103925. PubMed ID: 35671671
[TBL] [Abstract][Full Text] [Related]
10. The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
Mostert J; Heersema T; Mahajan M; Van Der Grond J; Van Buchem MA; De Keyser J
ISRN Neurol; 2013; 2013():370943. PubMed ID: 23984093
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
12. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Solanky BS; John NA; DeAngelis F; Stutters J; Prados F; Schneider T; Parker RA; Weir CJ; Monteverdi A; Plantone D; Doshi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
[TBL] [Abstract][Full Text] [Related]
13. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
[TBL] [Abstract][Full Text] [Related]
14. Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
Li V; Leurent B; Barkhof F; Braisher M; Cafferty F; Ciccarelli O; Eshaghi A; Gray E; Nicholas JM; Parmar M; Peryer G; Robertson J; Stallard N; Wason J; Chataway J
Neurology; 2022 May; 98(18):754-764. PubMed ID: 35321926
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
17. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.
Sijens PE; Mostert JP; Irwan R; Potze JH; Oudkerk M; De Keyser J
Psychiatry Res; 2008 Dec; 164(3):274-82. PubMed ID: 19017554
[TBL] [Abstract][Full Text] [Related]
18. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
